These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 24166760)
21. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study. Takizawa M; Hatta T; Iitsuka H; Katashima M; Sato Y; Kuroishi K; Nagashima H Clin Ther; 2020 May; 42(5):906-923. PubMed ID: 32456804 [TBL] [Abstract][Full Text] [Related]
22. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers. Addy C; Rothenberg P; Li S; Majumdar A; Agrawal N; Li H; Zhong L; Yuan J; Maes A; Dunbar S; Cote J; Rosko K; Van Dyck K; De Lepeleire I; de Hoon J; Van Hecken A; Depré M; Knops A; Gottesdiener K; Stoch A; Wagner J J Clin Pharmacol; 2008 Jun; 48(6):734-44. PubMed ID: 18508950 [TBL] [Abstract][Full Text] [Related]
23. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity. Yazawa R; Ishida M; Balavarca Y; Hennige AM Diabetes Obes Metab; 2023 Jul; 25(7):1973-1984. PubMed ID: 36974349 [TBL] [Abstract][Full Text] [Related]
24. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E; Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995 [TBL] [Abstract][Full Text] [Related]
25. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906. Jungnik A; Arrubla Martinez J; Plum-Mörschel L; Kapitza C; Lamers D; Thamer C; Schölch C; Desch M; Hennige AM Diabetes Obes Metab; 2023 Apr; 25(4):1011-1023. PubMed ID: 36527386 [TBL] [Abstract][Full Text] [Related]
26. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Aronne LJ; Tonstad S; Moreno M; Gantz I; Erondu N; Suryawanshi S; Molony C; Sieberts S; Nayee J; Meehan AG; Shapiro D; Heymsfield SB; Kaufman KD; Amatruda JM Int J Obes (Lond); 2010 May; 34(5):919-35. PubMed ID: 20157323 [TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. Addy C; Li S; Agrawal N; Stone J; Majumdar A; Zhong L; Li H; Yuan J; Maes A; Rothenberg P; Cote J; Rosko K; Cummings C; Warrington S; Boyce M; Gottesdiener K; Stoch A; Wagner J J Clin Pharmacol; 2008 Apr; 48(4):418-27. PubMed ID: 18258750 [TBL] [Abstract][Full Text] [Related]
28. Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective α-melanocyte-stimulating hormone (α-MSH) analogues. Conde-Frieboes K; Thøgersen H; Lau JF; Sensfuss U; Hansen TK; Christensen L; Spetzler J; Olsen HB; Nilsson C; Raun K; Dahl K; Hansen BS; Wulff BS J Med Chem; 2012 Mar; 55(5):1969-77. PubMed ID: 22335602 [TBL] [Abstract][Full Text] [Related]
29. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M; Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects. Muirhead GJ; Osterloh IH; Whaley S; van den Berg F J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858 [TBL] [Abstract][Full Text] [Related]
31. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults. Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667 [TBL] [Abstract][Full Text] [Related]
32. Novel α-MSH analog causes weight loss in obese rats and minipigs and improves insulin sensitivity. Fosgerau K; Raun K; Nilsson C; Dahl K; Wulff BS J Endocrinol; 2014 Feb; 220(2):97-107. PubMed ID: 24204009 [TBL] [Abstract][Full Text] [Related]
33. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040 [TBL] [Abstract][Full Text] [Related]
34. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Patat A; Parks V; Raje S; Plotka A; Chassard D; Le Coz F Br J Clin Pharmacol; 2009 Mar; 67(3):299-308. PubMed ID: 19523013 [TBL] [Abstract][Full Text] [Related]
35. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM; J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Sinetrol-XPur on Weight and Body Fat Reduction in Overweight or Obese Adults: A 12-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Trial. Park SJ; Sharma A; Bae MH; Sung HC; Kim NK; Sung E; Lee HJ J Med Food; 2020 Mar; 23(3):335-342. PubMed ID: 32130058 [TBL] [Abstract][Full Text] [Related]
37. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macimorelin in healthy adults: Results of a single-dose, randomized controlled study. Klaus B; Sachse R; Ammer N; Kelepouris N; Ostrow V Growth Horm IGF Res; 2020 Jun; 52():101321. PubMed ID: 32325373 [TBL] [Abstract][Full Text] [Related]
38. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. Palmer M; Jennings L; Silberg DG; Bliss C; Martin P BMC Pharmacol Toxicol; 2018 Mar; 19(1):10. PubMed ID: 29548345 [TBL] [Abstract][Full Text] [Related]
39. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, Safety, and Tolerability of Single Oral Doses of a Novel Oxytocin Receptor Antagonist-Cligosiban-in Development for Premature Ejaculation: Three Randomized Clinical Trials in Healthy Subjects. Osterloh IH; Muirhead GJ; Sultana S; Whaley S; van den Berg F; Atiee G J Sex Med; 2018 Nov; 15(11):1547-1557. PubMed ID: 30341006 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]